Avenue Therapeutics Announces Publication of Tramadol Non-Medical Use in Four European Countries: A Comparative Analysis
December 18 2020 - 8:00AM
Avenue Therapeutics, Inc. (NASDAQ: ATXI) (Avenue), a company
focused on the development of intravenous (IV) tramadol for the
U.S. market, today announced that a publication titled “Tramadol
Non-Medical Use in Four European Countries: A Comparative Analysis”
has been published in Drug and Alcohol Dependence, a peer-reviewed
international journal devoted to research, reviews, commentaries,
and policy analyses in the area of drug, alcohol and tobacco use
and dependence. The publication can be accessed here.
“The goal of the study is to better understand
the misuse and abuse of tramadol in countries where parenteral
tramadol is available, which requires consistent measures of misuse
behaviors and prevalence between countries. We evaluated tramadol
compared to conventional opioids by utilizing a harmonized
validated national survey across four countries: Germany, Italy,
Spain, and the United Kingdom (UK),” commented Janetta L. Iwanicki,
M.D., the paper’s lead author and Scientific Director of Research,
Rocky Mountain Poison & Drug Safety. “Despite high
availability, tramadol has a low rate of misuse and abuse in the
four countries. Importantly, consistent with previous literature,
misuse of tramadol by injection, an important marker of risk
behavior, is rare in these countries.”
In this study, data from the RADARS® System’s
Survey of Non-Medical Use of Prescription Drugs (NMURx) Program
online cross-sectional general population national surveys are
analyzed from 2018 from four countries, Germany, Italy, Spain, and
the UK, with 45,000 total responses. Misuse and abuse of tramadol,
codeine, morphine, and oxycodone are compared, with national
prevalence estimates calculated via calibration weighting. Rates
are calculated per population and per drug availability with
supplemental data included from patients entering treatment centers
and poison center exposures. The paper concluded that tramadol
misuse and abuse are infrequent both in absolute number of cases
and in comparison to conventional opioids, and that, even with
availability of intravenous tramadol formulations, misuse by
injection is rare.
About Avenue TherapeuticsAvenue Therapeutics is
a specialty pharmaceutical company whose mission is to develop IV
tramadol, a potential alternative that could reduce the use of
conventional opioids, for patients suffering from acute pain in the
U.S. Avenue is headquartered in New York City and was founded by
Fortress Biotech, Inc. (NASDAQ: FBIO). For more information, visit
www.avenuetx.com.
About Rocky Mountain Poison & Drug
SafetyRocky Mountain Poison & Drug Safety provides
specialized services spanning the lifecycle of a drug or consumer
product to public health, government agencies, and the
pharmaceutical and consumer products industries. Rocky Mountain
Poison & Drug Safety’s Poison Center & Health Information
and Drug & Consumer Product Services groups provide 24/7/365
contact center communication, exposure management, and toxicology
consulting. Rocky Mountain Poison & Drug Safety offers
research, analysis and surveillance, and consulting through its
Research & Consulting Services group, including its
industry-leading RADARS® system. For more information visit
http://www.rmpds.org.
About RADARS® SystemThe RADARS System is
supported by subscriptions from pharmaceutical manufacturers,
government and non-government agencies for surveillance, research
and reporting services. RADARS System is the property of Denver
Health and Hospital Authority, a political subdivision of the State
of Colorado. Denver Health retains exclusive ownership of all data,
databases and systems. Subscribers do not participate in data
collection nor do they have access to the raw data.
Forward-Looking StatementsThis
press release may contain “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, each as amended. Such
statements include, but are not limited to, any statements relating
to our growth strategy and product development programs and any
other statements that are not historical facts. Forward-looking
statements are based on management’s current expectations and are
subject to risks and uncertainties that could negatively affect our
business, operating results, financial condition and stock value.
Factors that could cause actual results to differ materially from
those currently anticipated include: risks related to us obtaining
regulatory approval from the FDA for our product candidate, risks
relating to the COVID-19 outbreak and its potential impact on our
employees’ and consultants’ ability to complete work in a timely
manner, risks relating to our growth strategy; risks relating to
the results of research and development activities; risks relating
to the timing of starting and completing clinical trials; our
ability to obtain, perform under and maintain financing and
strategic agreements and relationships; uncertainties relating to
preclinical and clinical testing; our dependence on third-party
suppliers; our ability to attract, integrate and retain key
personnel; the early stage of products under development; our need
for substantial additional funds; government regulation; patent and
intellectual property matters; competition; as well as other risks
described in our SEC filings. We expressly disclaim any obligation
or undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change
in our expectations or any changes in events, conditions or
circumstances on which any such statement is based, except as
required by law, and we claim the protection of the safe harbor for
forward-looking statements contained in the Private Securities
Litigation Reform Act of 1995.
Contacts: Jaclyn Jaffe and William BegienAvenue
Therapeutics, Inc. (781) 652-4500ir@avenuetx.com
Fortress Biotech (NASDAQ:FBIO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Fortress Biotech (NASDAQ:FBIO)
Historical Stock Chart
From Sep 2023 to Sep 2024